Outpatient step-up dosing of bispecific antibodies in relapsed or refractory multiple myeloma: an oncology nursing framework for monitoring and supportive care - Scorecard - MDSpire
Advertisement
Outpatient step-up dosing of bispecific antibodies in relapsed or refractory multiple myeloma: an oncology nursing framework for monitoring and supportive care
Clinical Scorecard: Ambulatory Step-Up Dosing of Bispecific Antibodies for Relapsed or Refractory Multiple Myeloma: A Framework for Oncology Nursing in Monitoring and Supportive Care
At a Glance
Category
Detail
Condition
Relapsed or Refractory Multiple Myeloma
Key Mechanisms
T-cell-redirecting bispecific antibodies engage CD3 on T cells and tumor-associated antigens on myeloma cells, primarily BCMA or GPRC5D.
Target Population
Patients with relapsed or refractory multiple myeloma requiring additional treatment options.
Care Setting
Ambulatory care settings with a focus on outpatient step-up dosing.
Key Highlights
Bispecific antibodies have expanded treatment options for RRMM.
Step-up dosing is critical to mitigate early immune-mediated toxicity.
Patient selection should consider clinical stability, disease burden, and caregiver reliability.
Outpatient initiation requires a biologically informed and resource-stratified model.
Monitoring for CRS and neurotoxicity is essential during treatment.
Guideline-Based Recommendations
Diagnosis
Diagnosis of multiple myeloma should be confirmed through clinical and laboratory evaluations.
Management
Utilize product-specific step-up dosing to reduce the risk of severe early toxicity.
Monitoring & Follow-up
Implement monitoring protocols for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
Risks
Be aware of risks including CRS, ICANS, cytopenias, infections, and hypogammaglobulinemia.
Patient & Prescribing Data
Patients with relapsed or refractory multiple myeloma.
Outpatient step-up dosing is a selective high-acuity care model rather than a routine efficiency strategy.
Clinical Best Practices
Integrate clinical operations with underlying disease biology for safe ambulatory initiation.
Use decision matrices for monitoring and candidate assessment.
Conduct continuous program evaluation to improve safety and efficacy.
The tool, called PANGEA-SMM, outperforms existing predictive tools by more accurately determining when smoldering multiple myeloma is progressing and requires treatment. The free online tool can be used immediately to monitor patients.
